China ADR Privatizations: The Challenges of Getting the Best Deal
The stellar performance of China’s stock markets over the past twelve months (Shanghai +121%, Shenzhen +161%, and Hong Kong +17%) has led to a...
605 Views
Pre-IPO Shenzhen Salubris Pharmaceuticals (A/H Listing) - Innovative Drug Business Has Been on Track
​Salubris shift focus to innovative drug ecosystem centered on CKM,aiming to be a chronic disease management company,with potential for higher...
192 Views
Opening of E-commerce Channel to Change China's Drug Market
Numerous press outlets report that China’s Food & Drug Administration (CFDA) will release regulations permitting online sales of...
602 Views
Introducing Long Term Leaders - Focussed Insights for your Core Holdings
We are pleased to announce the roll out of our latest content vertical: Long Term Leaders. Under this category,  we have identified companies that...
497 Views
Pre-IPO Atom Therapeutics - About The Pipeline and the Concerns Behind
The core of Atom's R&D model is its "structure-metabolism analysis-driven drug discovery platform". Peak sales of ABP-671 and ABP-745 will be...
280 Views